The Sevillian biotech Universal DX captures 14 million for its colon cancer test


Updated:14/01/2021 07:24h


The funding round opened by the Sevillian biotechnology Universal DX (UDX) It has exceeded all forecasts, since the company founded by Juan Martínez Barea has raised 14 million euros in 2020, four million more than initially planned. The round, covered by the company’s own shareholders, will allow the company to continue with its clinical trials, complete the colon cancer detection test this year with the intention of launching it on the market in 2022 with a reliability of more than 90% .

Created in 2012 in Seville, Universal DX has already raised 35 million euros: 30 million among private investors and 5 million euros in the public sector, since it raised funds


Share on facebook
Share on pinterest
Share on twitter
Share on linkedin
Share on email


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.